Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 5/20 | 0.33 |
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14312210 | 0.94 | MAPT (0.40) | MAPTMAPK1CDK1CDK5 | |
| SCHEMBL14312165 | 0.90 | MAPT (0.40) | MAPTMAPK1CDK1CDK5 | |
| SCHEMBL14312160 | 0.90 | MAPT (0.42) | MAPTMAPK1CRHR1 | |
| SCHEMBL14312253 | 0.87 | MAPT (0.42) | MAPTMAPK1CRHR1 | |
| SCHEMBL14236926 | 0.85 | CRHR1 (0.40) | CRHR1CDK1CDK5 | |
| SCHEMBL14236937 | 0.85 | CRHR1 (0.40) | CRHR1CDK1CDK5 | |
| SCHEMBL14312193 | 0.82 | POLB (0.33) | CRHR1CDK1CDK5 | |
| SCHEMBL14312207 | 0.79 | GAA (0.43) | MAPTMAPK1CRHR1 | |
| SCHEMBL14236923 | 0.77 | CDK1 (0.37) | CRHR1CDK1CDK5 | |
| SCHEMBL14236888 | 0.76 | ALDH1A1 (0.40) | CDK1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987383-B2 | Triazine derivatives and application thereof | NIPPON KASEI CHEMICAL COMPANY LIMITED (JP) | 2015-03-24 | — | — | US | disclosed |
| US-20130023629-A1 | TRIAZINE DERIVATIVES AND APPLICATION THEREOF | SHINRYO CORPORATION (JP) | 2013-01-24 | — | — | US | disclosed |
| EP-2537833-A1 | TRIAZINE DERIVATIVE, AND APPLICATION THEREOF | Nippon Kasei Chemical Company Limited (JP) | 2012-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023629-A1 | TRIAZINE DERIVATIVES AND APPLICATION THEREOF | HSPH1, PRDX3, PRXL2A | MAPT 2771/4885MAPK1 4162/4885CRHR1 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.